The latest price of Sotorasib in 2024 is released!

Sotorasib is a new type of anti-cancer drug that belongs to the category of targeted therapy drugs. Its main area of u200bu200bapplication is the treatment of non-small cell lung cancer (NSCLC), especially those carrying the KRAS G12C mutation.

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.

KRAS G12C mutation is a common gene mutation in various cancers, especially in non-small cell lung cancer. This mutation causes abnormal cell signaling pathways that drive cancer cells to overgrow and spread. The uniqueness of sotorasiib is that it inhibits the growth and spread of cancer cells by targeting the KRAS G12C mutation and interfering with abnormal signaling pathways.

The development of this drug marks a breakthrough for theKRAS G12C mutation, which has long been considered difficult to intervene. The mechanism of action of sotoracib involves binding to the KRAS G12C mutation. By inhibiting its activity, it blocks abnormal signaling within cancer cells, thereby combating the development of lung cancer.

Sotoraxib is an oral medication, and the dosage and regimen are usually determined based on the patient's specific condition and the recommendations of the physician. Before use, patients typically undergo genetic testing to confirm whether their tumors carry the KRAS G12C mutation and thus determine whether they are candidates for the drug.

Although sotoracib provides a new treatment option for patients with KRAS G12C mutated non-small cell lung cancer, it is not suitable for all patients with non-small cell lung cancer. Patients need to closely follow their doctor's recommendations when using sotoraxib and receive regular monitoring and follow-up to ensure the effectiveness and safety of the drug. Overall, sotorasiib represents an important advance in the field of cancer treatment for precision treatment of specific genetic mutations.